Study guide
3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations
PEBC Pharmacist Evaluating Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape
1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation
2 Chapter 2: Pharmaceutics & Drug Delivery Systems
2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence
3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application
4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics
4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics
5 Chapter 5: Pathophysiology & Clinical Assessment
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing
6 Chapter 6: Pharmacotherapy & Minor Ailments
6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine
7 Chapter 7: Special Populations & Applied Therapeutics
7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment
8 Chapter 8: Prescription Processing, Calculations & Compounding
8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation
9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics
9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health
10 Chapter 10: Evidence Appraisal, Safety & Practice Management
10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada
11 Chapter 11: Patient Care Process, Communication & Collaborative Practice
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care
12 Chapter 12: Medication Administration, Devices & Expanded Scope
12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
13 Chapter 13: Pharmacy Management, Finance & Practice Leadership
13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety
3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations
Key Takeaways Explain This Topic AI
In linear (first-order) pharmacokinetics, clearance and half-life remain constant across doses, producing proportional changes in steady-state concentration with dose adjustments.
Non-linear (Michaelis-Menten) kinetics, exemplified by phenytoin, occur when metabolic enzyme pathways saturate, causing disproportionate surges in steady-state concentration with small dosage increments.
Steady state is reached after approximately 4 to 5 elimination half-lives during constant-rate intravenous infusion or regular intermittent dosing, independent of the dose magnitude or dosing interval.
The loading dose depends strictly on the target concentration and apparent volume of distribution (LD = Vd * Ctarget / F), whereas the maintenance dose depends on systemic clearance (MD = CL * Ctarget * tau / F).
Creatinine clearance estimation via the Cockcroft-Gault equation is the clinical standard for drug dosing adjustments, utilizing ideal body weight (IBW) in non-obese individuals and adjusted body weight (AdjBW) in obesity.
Last updated: August 2026
3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations
Clinical pharmacokinetics applies mathematical models to describe and predict the time course of drug concentrations in biological fluids. Mastery of kinetic modeling and dosing equations enables the pharmacist to design individualized dosage regimens that optimize therapeutic efficacy while preventing toxicity.
1. Compartmental Pharmacokinetic Models +-------------------------------------------------------------------------------------+
- | ONE-COMPARTMENT vs. TWO-COMPARTMENT MODELS |
- +-------------------------------------------------------------------------------------+
- | ONE-COMPARTMENT OPEN MODEL: |
- | |
- | [ Dose (IV / Oral) ] ===> [ Central Compartment (Vd) ] ===> [ Elimination (ke) ] |
- | |
- | TWO-COMPARTMENT OPEN MODEL: |
- | |
- | k12 |
- | [ Central Compartment (V1) ] <===> [ Peripheral Compartment (V2) ] |
- | | k21 (Muscle, Adipose, Bone) |
- | v ke |
- | [ Elimination ] |
- +-------------------------------------------------------------------------------------+
- One-Compartment Open Model
Assumes the human body behaves as a single, instantaneously well-mixed kinetic compartment. Following an intravenous bolus injection, drug distribution between vascular fluid and tissues occurs instantaneously: C ( t ) = C 0 ⋅ e − k e ⋅ t C(t) = C_0 \cdot e^{-k_e \cdot t} C ( t ) = C 0 ⋅ e − k e ⋅ t ln C ( t ) = ln C 0 − k e ⋅ t \ln C(t) = \ln C_0 - k_e \cdot t ln C ( t ) = ln C 0 − k e ⋅ t
Where C 0 = Dose / V d C_0 = \text{Dose} / V_d C 0 = Dose / V d , and k e k_e k e is the first-order elimination rate constant.
Two-Compartment Open Model
Drugs do not distribute instantaneously into all tissues. Tissues with high blood flow (heart, liver, lungs, kidneys, brain) comprise the Central Compartment ( V 1 V_1 V 1 ) , while poorly perfused tissues (muscle, skin, adipose) comprise the Peripheral Compartment ( V 2 V_2 V 2 ) .
Following an IV dose, the plasma concentration decline is biexponential: C ( t ) = A ⋅ e − α ⋅ t + B ⋅ e − β ⋅ t C(t) = A \cdot e^{-\alpha \cdot t} + B \cdot e^{-\beta \cdot t} C ( t ) = A ⋅ e − α ⋅ t + B ⋅ e − β ⋅ t
Distribution Phase ( α \alpha α -phase) : Rapid initial decline in plasma concentration driven by drug moving from the central compartment into peripheral tissues.
Elimination Phase ( β \beta β -phase) : Slower terminal decline reflecting irreversible drug elimination from the body once equilibrium between central and peripheral compartments is established.
Clinical Relevance : Therapeutic drug concentrations must be sampled during the post-distribution β \beta β -phase (e.g., waiting 6 − 8 hours 6-8\text{ hours} 6 − 8 hours post-dose for oral digoxin , or 1 − 2 hours 1-2\text{ hours} 1 − 2 hours post-infusion for vancomycin ).
2. Elimination Kinetics: First-Order, Zero-Order, and Michaelis-Menten +-------------------------------------------------------------------------------------+
- | ELIMINATION KINETICS PROFILES |
- +-------------------------------------------------------------------------------------+
- | First-Order Kinetics (Linear) : dC/dt = -ke * C |
- | - Constant Fraction eliminated per unit time (e.g., 20%/hr) |
- | - Constant t(1/2) and Constant Clearance (CL) |
- | - Css is directly proportional to dose (Double dose -> Double Css) |
- | |
- | Zero-Order Kinetics (Saturable) : dC/dt = -k0 |
- | - Constant Amount eliminated per unit time (e.g., 10 mg/hr) |
- | - t(1/2) increases as concentration increases; Clearance decreases |
- | - E.g., High-dose Ethanol, Aspirin overdose |
- | |
- | Michaelis-Menten Kinetics (Mixed) : dC/dt = -(Vmax * C) / (Km + C) |
- | - At C << Km: Behaves as First-Order |
- | - At C >> Km: Behaves as Zero-Order (Saturated enzymes) |
- | - Small dose increase -> Disproportionate surge in Css |
- | - Classic Example: Phenytoin |
- +-------------------------------------------------------------------------------------+
- Phenytoin Michaelis-Menten Dynamics
Phenytoin biotransformation by hepatic CYP2C9 and CYP2C19 becomes saturated within the standard therapeutic range ( 10 − 20 mg/L 10 - 20\text{ mg/L} 10 − 20 mg/L or 40 − 80 μ mol/L 40 - 80\text{ }\mu \text{mol/L} 40 − 80 μ mol/L ): Daily Dose Rate ( R ) = V max ⋅ C s s K m + C s s \text{Daily Dose Rate } (R) = \frac{V_{\text{max}} \cdot C_{ss}}{K_m + C_{ss}} Daily Dose Rate ( R ) = K m + C ss V max ⋅ C ss Steady-State Concentration ( C s s ) = K m ⋅ R V max − R \text{Steady-State Concentration } (C_{ss}) = \frac{K_m \cdot R}{V_{\text{max}} - R} Steady-State Concentration ( C ss ) = V max − R K m ⋅ R
Where typical population parameters are V max ≈ 7 mg/kg/day V_{\text{max}} \approx 7\text{ mg/kg/day} V max ≈ 7 mg/kg/day ( 400 − 600 mg/day 400 - 600\text{ mg/day} 400 − 600 mg/day ) and K m ≈ 4 mg/L K_m \approx 4\text{ mg/L} K m ≈ 4 mg/L ( 16 μ mol/L 16\text{ }\mu \text{mol/L} 16 μ mol/L ).
Clinical Warning : As R R R approaches V max V_{\text{max}} V max , the denominator ( V max − R V_{\text{max}} - R V max − R ) approaches zero, precipitating an exponential surge in C s s C_{ss} C ss . When phenytoin levels are 12 mg/L 12\text{ mg/L} 12 mg/L , increasing the daily dose by as little as 25 − 50 mg/day 25 - 50\text{ mg/day} 25 − 50 mg/day can double the plasma concentration, causing neurotoxicity.
3. Fundamental Pharmacokinetic Parameters and Formulas +-------------------------------------------------------------------------------------+
- | KEY PHARMACOKINETIC FORMULAS |
- +-------------------------------------------------------------------------------------+
- | 1. Elimination Rate Constant (ke) : ke = ln(C1 / C2) / (t2 - t1) = CL / Vd |
- | 2. Elimination Half-Life (t1/2) : t1/2 = 0.693 / ke = (0.693 * Vd) / CL |
- | 3. Systemic Clearance (CL) : CL = ke * Vd = Dose(IV) / AUC0-inf |
- | 4. Loading Dose (LD) : LD = (Vd * Ctarget) / F |
- | 5. Maintenance Dose (MD) : MD = (CL * Ctarget * tau) / F |
- | 6. Average Steady State (Css,avg) : Css,avg = (F * Dose) / (CL * tau) |
- | 7. Accumulation Factor (Racc) : Racc = 1 / (1 - e^(-ke * tau)) |
- +-------------------------------------------------------------------------------------+
- Mathematical Interrelationships
Elimination Rate Constant ( k e k_e k e ) : k e = ln ( C 1 ) − ln ( C 2 ) t 2 − t 1 = ln ( C 1 / C 2 ) Δ t k_e = \frac{\ln(C_1) - \ln(C_2)}{t_2 - t_1} = \frac{\ln(C_1 / C_2)}{\Delta t} k e = t 2 − t 1 ln ( C 1 ) − ln ( C 2 ) = Δ t ln ( C 1 / C 2 )
Elimination Half-Life ( t 1 / 2 t_{1/2} t 1/2 ) : t 1 / 2 = ln ( 2 ) k e = 0.693 k e = 0.693 ⋅ V d C L t_{1/2} = \frac{\ln(2)}{k_e} = \frac{0.693}{k_e} = \frac{0.693 \cdot V_d}{CL} t 1/2 = k e ln ( 2 ) = k e 0.693 = C L 0.693 ⋅ V d
Steady-State Principle : The time required to achieve steady-state during repeated dosing depends only on the elimination half-life ( t 1 / 2 t_{1/2} t 1/2 ) , not on the dose or dosing interval:
- 1 × t 1 / 2 = 50 % 1 \times t_{1/2} = 50\% 1 × t 1/2 = 50% of steady state
- 2 × t 1 / 2 = 75 % 2 \times t_{1/2} = 75\% 2 × t 1/2 = 75% of steady state
- 3.32 × t 1 / 2 = 90 % 3.32 \times t_{1/2} = 90\% 3.32 × t 1/2 = 90% of steady state
4 to 5 × t 1 / 2 = 93.75 % − 96.88 % 4 \text{ to } 5 \times t_{1/2} = 93.75\% - 96.88\% 4 to 5 × t 1/2 = 93.75% − 96.88% (clinically considered true steady state)
Systemic Clearance ( C L CL C L ) :
Clearance represents the intrinsic volume of biological fluid completely cleared of drug per unit time (expressed in L/h \text{L/h} L/h or mL/min \text{mL/min} mL/min ): C L = k e ⋅ V d = F ⋅ Dose AUC 0 − ∞ CL = k_e \cdot V_d = \frac{F \cdot \text{Dose}}{\text{AUC}_{0-\infty}} C L = k e ⋅ V d = AUC 0 − ∞ F ⋅ Dose
- 4. Dosing Calculations: Loading Doses, Maintenance Doses, and Accumulation
- Loading Dose ( L D LD L D )
A loading dose rapidly achieves the target therapeutic plasma concentration without waiting for 4 − 5 half-lives 4-5\text{ half-lives} 4 − 5 half-lives of steady-state accumulation. It depends strictly on the volume of distribution ( V d V_d V d ) : L D = V d ⋅ C target F LD = \frac{V_d \cdot C_{\text{target}}}{F} L D = F V d ⋅ C target
If a baseline drug concentration ( C initial C_{\text{initial}} C initial ) is already present: L D = V d ⋅ ( C target − C initial ) F LD = \frac{V_d \cdot (C_{\text{target}} - C_{\text{initial}})}{F} L D = F V d ⋅ ( C target − C initial )
Maintenance Dose ( M D MD M D )
The maintenance dose replaces drug lost via systemic clearance during each dosing interval ( τ \tau τ ): M D = C L ⋅ C target ⋅ τ F = k e ⋅ V d ⋅ C target ⋅ τ F MD = \frac{CL \cdot C_{\text{target}} \cdot \tau}{F} = \frac{k_e \cdot V_d \cdot C_{\text{target}} \cdot \tau}{F} M D = F C L ⋅ C target ⋅ τ = F k e ⋅ V d ⋅ C target ⋅ τ
Peak and Trough Concentrations at Steady State (Intermittent IV Infusion)
For a drug administered as a short intravenous infusion of duration T inf T_{\text{inf}} T inf with dosing interval τ \tau τ : C max , s s = Dose ⋅ ( 1 − e − k e ⋅ T inf ) T inf ⋅ k e ⋅ V d ⋅ ( 1 − e − k e ⋅ τ ) C_{\text{max},ss} = \frac{\text{Dose} \cdot (1 - e^{-k_e \cdot T_{\text{inf}}})}{T_{\text{inf}} \cdot k_e \cdot V_d \cdot (1 - e^{-k_e \cdot \tau})} C max , ss = T inf ⋅ k e ⋅ V d ⋅ ( 1 − e − k e ⋅ τ ) Dose ⋅ ( 1 − e − k e ⋅ T inf ) C min , s s = C max , s s ⋅ e − k e ⋅ ( τ − T inf ) C_{\text{min},ss} = C_{\text{max},ss} \cdot e^{-k_e \cdot (\tau - T_{\text{inf}})} C min , ss = C max , ss ⋅ e − k e ⋅ ( τ − T inf )
5. Renal Function Assessment: The Cockcroft-Gault Equation
In Canadian pharmacy practice and drug monographs, dosage adjustments for renally eliminated drugs (e.g., direct oral anticoagulants, aminoglycosides, vancomycin, gabapentin, low-molecular-weight heparins) are based on the Cockcroft-Gault estimated creatinine clearance (CrCl) .
Ideal Body Weight (IBW) Formulas IBW male = 50 kg + 2.3 ⋅ ( Height in inches − 60 ) \text{IBW}_{\text{male}} = 50\text{ kg} + 2.3 \cdot (\text{Height in inches} - 60) IBW male = 50 kg + 2.3 ⋅ ( Height in inches − 60 ) IBW female = 45.5 kg + 2.3 ⋅ ( Height in inches − 60 ) \text{IBW}_{\text{female}} = 45.5\text{ kg} + 2.3 \cdot (\text{Height in inches} - 60) IBW female = 45.5 kg + 2.3 ⋅ ( Height in inches − 60 )
Non-Obese Patients ( Actual Weight ≤ IBW \text{Actual Weight} \le \text{IBW} Actual Weight ≤ IBW ) : Use Actual Body Weight (ABW) .
Normal Overweight ( A B W = 1.0 − 1.2 × I B W ABW = 1.0 - 1.2 \times IBW A B W = 1.0 − 1.2 × I B W ) : Use IBW .
Obese Patients ( A B W > 1.2 × I B W ABW > 1.2 \times IBW A B W > 1.2 × I B W or 120 % 120\% 120% of IBW) : Use Adjusted Body Weight (AdjBW) : AdjBW = IBW + 0.4 ⋅ ( Actual Weight − IBW ) \text{AdjBW} = \text{IBW} + 0.4 \cdot (\text{Actual Weight} - \text{IBW}) AdjBW = IBW + 0.4 ⋅ ( Actual Weight − IBW )
Cockcroft-Gault Equations Using Canadian SI Units (Serum Creatinine S c r in μ mol/L ) : \text{Using Canadian SI Units (Serum Creatinine } S_{cr} \text{ in } \mu\text{mol/L}): Using Canadian SI Units (Serum Creatinine S cr in μ mol/L ) : CrCl (mL/min) = ( 140 − Age ) ⋅ Weight (kg) S c r ( μ mol/L ) ⋅ 1.2 (males; multiply by 0.85 for females) \text{CrCl (mL/min)} = \frac{(140 - \text{Age}) \cdot \text{Weight (kg)}}{S_{cr} (\mu\text{mol/L})} \cdot 1.2 \text{ (males; multiply by } 0.85 \text{ for females)} CrCl (mL/min) = S cr ( μ mol/L ) ( 140 − Age ) ⋅ Weight (kg) ⋅ 1.2 (males; multiply by 0.85 for females) Using Conventional Units (Serum Creatinine S c r in mg/dL ) : \text{Using Conventional Units (Serum Creatinine } S_{cr} \text{ in mg/dL}): Using Conventional Units (Serum Creatinine S cr in mg/dL ) : CrCl (mL/min) = ( 140 − Age ) ⋅ Weight (kg) 72 ⋅ S c r ( mg/dL ) ⋅ ( 0.85 for females, 1.00 for males ) \text{CrCl (mL/min)} = \frac{(140 - \text{Age}) \cdot \text{Weight (kg)}}{72 \cdot S_{cr} (\text{mg/dL})} \cdot (0.85 \text{ for females, } 1.00 \text{ for males}) CrCl (mL/min) = 72 ⋅ S cr ( mg/dL ) ( 140 − Age ) ⋅ Weight (kg) ⋅ ( 0.85 for females, 1.00 for males )
(Conversion Factor: S c r in μ mol/L = S c r in mg/dL × 88.4 S_{cr} \text{ in } \mu\text{mol/L} = S_{cr} \text{ in mg/dL} \times 88.4 S cr in μ mol/L = S cr in mg/dL × 88.4 ) .
Which constant does the exam expect? The PEBC reference sheet supplied on screen during the Evaluating Examination gives the male form as (140 minus age) x actual body weight (kg) x 1.2 divided by serum creatinine in micromol/L, with the female value obtained by multiplying the male result by 0.85 (an effective factor of about 1.02). Many textbooks print 1.23 and 1.04 instead; the two forms differ by under 3% and rarely change a dosing band, but answer with the sheet you are given.